

Engineering Conferences International ECI Digital Archives

Integrated Continuous Biomanufacturing II

Proceedings

Fall 11-2-2015

Pilot scale hybrid fed batch and continuous processing of biologics

Dave Sullivan

Pfizer, david.sullivan@pfizer.com

Michael O'Connor

Pfizer

Samir Gondalia

Pfizer

Matt Gagnon

Pfizer

Follow this and additional works at: http://dc.engconfintl.org/biomanufact_ii



Part of the [Biomedical Engineering and Bioengineering Commons](#)

Recommended Citation

Dave Sullivan, Michael O'Connor, Samir Gondalia, and Matt Gagnon, "Pilot scale hybrid fed batch and continuous processing of biologics" in "Integrated Continuous Biomanufacturing II", Chetan Goudar, Amgen Inc. Suzanne Farid, University College London Christopher Hwang, Genzyme-Sanofi Karol Lacki, Novo Nordisk Eds, ECI Symposium Series, (2015). http://dc.engconfintl.org/biomanufact_ii/139

This Conference Proceeding is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Integrated Continuous Biomanufacturing II by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.

PILOT SCALE HYBRID FEB BATCH AND CONTINUOUS PROCESSING OF BIOLOGICS

Dave Sullivan, Pfizer
david.sullivan@pfizer.com
Michael O'Connor, Pfizer
Samir Gondalia, Pfizer
Matt Gagnon, Pfizer

Key Words: integrated, continuous, cell culture, bioreactor, perfusion

Pfizer Bioprocessing R&D is focused on developing enabling technologies that will reduce capital and operational expenses, decrease equipment scale, increase automation and utilize fewer FTEs. To realize this vision, our Pilot Facility has partnered with our cell culture process development colleagues to adapt a fed batch platform 150L stainless steel bioreactor to run in hybrid perfusion, standard perfusion, low volume cell controlled perfusion, and continuous stirred tank modes. Through adjustments to impeller configuration, sparging strategy, and addition ports the bioreactor was able to deliver multiple batches that produced ~3X gains in cell density and volumetric productivity versus conventional fed batch platform methods.